Mr. Fabrice Chouraqui, Ph D., has been Chief Executive Officer and Executive Director of Pharming Group N.V. since March 4, 2025. He has been the Chief Executive Officer-Partner of Flagship Pioneering and...

Leadership Team

Name	Position	Tenure	Compensation	Ownership
Sijmen de Vries	Advisor	no data	US$2.81m	2.13% € 11.8m
Fabrice Chouraqui	CEO & Executive Director	no data	no data	0.68% € 3.8m
Jeroen Wakkerman	Chief Financial Officer	4.3yrs	no data	0.063% € 350.5k
Mireille Sanders	Chief Operations Officer	5.6yrs	no data	0.12% € 650.0k
Susanne Embleton	Investor Relations Manager	no data	no data	no data
Ruud Van Outersterp	Chief Ethics & Compliance Officer	3.8yrs	no data	0.024% € 134.4k
Ines Bernal	Chief People Officer	less than a year	no data	no data
Anurag Relan	Chief Medical Officer	3.8yrs	no data	0.027% € 149.9k
Stephen Toor	Chief Commercial Officer & GM Americas	8.2yrs	no data	0.028% € 152.7k
Alexander Breidenbach	Chief Business Officer	1.5yrs	no data	0.0096% € 53.2k
Bruno M. Giannetti	Consultant	3.8yrs	no data	no data

3.8yrs

Average Tenure

58yo

Average Age

Experienced Management: PHARM's management team is considered experienced (3.8 years average tenure).

Board Members

Name	Position	Tenure	Compensation	Ownership
Fabrice Chouraqui	CEO & Executive Director	no data	no data	0.68% € 3.8m
Leonard Kruimer	Independent Non-Executive Director	3.8yrs	US$90.00k	0.018% € 98.6k
Mark Pykett	Independent Non-Executive Director	4.3yrs	US$87.00k	0.021% € 118.8k
Deborah Jorn	Independent Non-Executive Vice-Chairperson	5.8yrs	US$87.00k	0.024% € 131.5k
Steven Baert	Independent Non-Executive Director	3.8yrs	US$90.00k	0.018% € 98.6k
Barbara Yanni	Independent Non-Executive Director	4.3yrs	US$94.00k	0.021% € 118.8k
Richard Peters	Non-Executive Chairman of Board	1.5yrs	US$46.00k	0.0092% € 51.1k
Jabine van der Meijs	Independent Non-Executive Director	3.8yrs	US$94.00k	0.018% € 98.6k

3.8yrs

Average Tenure

62yo

Average Age

Experienced Board: PHARM's board of directors are considered experienced (3.8 years average tenure).

Company Analysis and Financial Data Status

Data	Last Updated (UTC time)
Company Analysis	2025/03/17 02:48
End of Day Share Price	2025/03/17 00:00
Earnings	2024/12/31
Annual Earnings	2024/12/31

Data Sources

The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.

Package	Data	Timeframe	Example US Source ^*
Company Financials	10 years	Income statement Cash flow statement Balance sheet	SEC Form 10-K SEC Form 10-Q
Analyst Consensus Estimates	+3 years	Forecast financials Analyst price targets	Analyst Research Reports Blue Matrix
Market Prices	30 years	Stock prices Dividends, Splits and Actions	ICE Market Data SEC Form S-1
Ownership	10 years	Top shareholders Insider trading	SEC Form 4 SEC Form 13D
Management	10 years	Leadership team Board of directors	SEC Form 10-K SEC Form DEF 14A
Key Developments	10 years	Company announcements	SEC Form 8-K

^* Example for US securities, for non-US equivalent regulatory forms and sources are used.

Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more.

Analysis Model and Snowflake

Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.

Learn about the world class team who designed and built the Simply Wall St analysis model.

Industry and Sector Metrics

Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on Github.

Analyst Sources

Pharming Group N.V. is covered by 14 analysts. 5 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.

Analyst	Institution
John Savin	Edison Investment Research
Simon Scholes	First Berlin Equity Research GmbH
Joseph Pantginis	H.C. Wainwright & Co.

Pharming Group Management

Management criteria checks 2/4

Key information

Recent management updates

Pharming Group N.V., Annual General Meeting, Jun 11, 2025

Pharming Group N.V. Announces CEO Changes

Insufficient new directors

Pharming Group N.V. Appoints Richard Peters as Non-Executive Director

Pharming Group N.V. Appoints Alexander Breidenbach as Chief Business Officer

Pharming Group N.V. Approves the Proposal to Reappoint Paul Sekhri, Chair of the Board, as Non-Executive Director for A Period of One Year Who Will Resign from the Board Upon Appointment of His Successor

Recent updates

Pharming Group N.V., Annual General Meeting, Jun 11, 2025

Full year 2024 earnings: EPS exceeds analyst expectations

Pharming Group N.V. to Report Q2, 2025 Results on Jul 31, 2025

Pharming Group N.V. Announces CEO Changes

Pharming Group N.V. to Report Q4, 2024 Results on Mar 13, 2025

Pharming Group N.V. (AMS:PHARM) Held Back By Insufficient Growth Even After Shares Climb 26%

Price target increased by 8.1% to €1.84

Pharming Group N.V. Announces Positive Topline Data in Pediatric Clinical Trial of Leniolisib

New major risk - Share price stability

Consensus estimates of losses per share improve by 14%

Third quarter 2024 earnings released: US$0.002 loss per share (vs US$0.005 profit in 3Q 2023)

Pharming Group Announces Start of Phase II Clinical Trial of Leniolisib for Primary Immunodeficiencies (PIDs) with Immune Dysregulation

New minor risk - Share price stability

Price target decreased by 7.8% to €1.78

New minor risk - Share price stability

Second quarter 2024 earnings released: US$0.002 loss per share (vs US$0.002 profit in 2Q 2023)

Insufficient new directors

Pharming Group N.V. Provides Update on Ongoing Regulatory Review of Leniolisib for the Treatment of Apds in the European Union

Pharming Group N.V. Provides Revenue Guidance for 2024

First quarter 2024 earnings released: US$0.019 loss per share (vs US$0.019 loss in 1Q 2023)

Pharming Group N.V. announced that it expects to receive €100 million in funding

Price target increased by 11% to €2.00

Full year 2023 earnings released: US$0.015 loss per share (vs US$0.021 profit in FY 2022)

Pharming Group N.V. to Report Q2, 2024 Results on Aug 01, 2024

Revenues Working Against Pharming Group N.V.'s (AMS:PHARM) Share Price

Consensus estimates of losses per share improve by 31%

Pharming Group N.V. to Report Q4, 2023 Results on Mar 14, 2024

Health Check: How Prudently Does Pharming Group (AMS:PHARM) Use Debt?

Consensus EPS estimates upgraded to US$0.014 loss, revenue downgraded

Consensus estimates of losses per share improve by 34%

New minor risk - Shareholder dilution

Third quarter 2023 earnings released: EPS: US$0.005 (vs US$0.014 in 3Q 2022)

Pharming Group N.V. Appoints Richard Peters as Non-Executive Director

Pharming Group N.V. (AMS:PHARM) Shares Could Be 49% Below Their Intrinsic Value Estimate

Consensus EPS estimates fall by 140%

Pharming Group N.V. Announces First Patient Enrolled in Phase Iii Clinical Trial of Leniolisib for the Treatment of Apds in Japan

First half 2023 earnings released: US$0.017 loss per share (vs US$0.03 profit in 1H 2022)

Pharming Group N.V. Appoints Alexander Breidenbach as Chief Business Officer

Now 20% undervalued

Health Check: How Prudently Does Pharming Group (AMS:PHARM) Use Debt?

Pharming Group N.V. Approves the Proposal to Reappoint Paul Sekhri, Chair of the Board, as Non-Executive Director for A Period of One Year Who Will Resign from the Board Upon Appointment of His Successor

Investor sentiment improves as stock rises 15%

Price target increased by 8.9% to €1.83

Investor sentiment improves as stock rises 18%

Full year 2022 earnings released: EPS: US$0.021 (vs US$0.025 in FY 2021)

Is Pharming Group (AMS:PHARM) Using Too Much Debt?

Pharming Group N.V. Provides Update on EMA Regulatory Review of Leniolisib for Apds in Europe

Pharming Group N.V.'s (AMS:PHARM) Intrinsic Value Is Potentially 41% Above Its Share Price

Now 20% undervalued

Now 20% undervalued

Investor sentiment improved over the past week

Pharming Group N.V. Announces Positive Interim Analysis Data from Open-Label Extension Study of Leniolisib in Presentation At the 64Th American Society of Hematology (ASH) Annual Meeting and Exposition

Pharming Group N.V. to Report Fiscal Year 2022 Results on Mar 16, 2023

Pharming Group N.V. Announces Positive Results of Phase 3 Clinical Trial of Investigational Drug Leniolisib

We Think Pharming Group (AMS:PHARM) Can Manage Its Debt With Ease

High number of new directors

Investor sentiment improved over the past week

Pharming Group N.V. Announces European Medicines Agency Validates its Marketing Authorisation Application Under Accelerated Assessment for Leniolisib

Third quarter 2022 earnings: EPS exceeds analyst expectations

Pharming Group N.V. Submits Marketing Authorisation Application to European Medicines Agency for Leniolisib

Price target increased to €13.52

Pharming Group N.V. Announces US FDA Acceptance for Priority Review of its New Drug Application for Leniolisib

Second quarter 2022 earnings released: EPS: US$0.025 (vs US$0.009 in 2Q 2021)

Is Pharming Group (AMS:PHARM) Using Too Much Debt?

Pharming Announces New ICD-10-CM Code for APDS, a Rare Primary Immunodeficiency

Pharming Group N.V. Receives Accelerated Assessment in Europe for Leniolisib for the Treatment of Rare Immunodeficiency, APDS

Consensus forecasts updated

First quarter 2022 earnings: EPS misses analyst expectations

GIMV NV (ENXTBR:GIMB) completed the acquisition of 20.87% stake in Bioconnection B.V. from Pharming Group N.V. (ENXTAM:PHARM).